Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease
Remo Panaccione(University of Calgary), Çharles N. Bernstein(University of Manitoba), Waqqas Afif, Mark Borgaonkar, John K. Marshall(McMaster University), Reena Khanna(University of Toronto), Alain Bitton(McGill University Health Centre), Grigorios I. Leontiadis(McMaster University), Laura E. Targownik(University of Manitoba), Paul Moayyedi(McMaster University Medical Centre), Edward V. Loftus(Mayo Clinic), Sanjay K. Murthy(University of Ottawa), Brian Bressler(University of British Columbia), A. Hillary Steinhart(Mount Sinai Hospital), Jennifer Jones(Dalhousie University), Erin Kennedy(Mount Sinai Hospital), Cynthia H. Seow(University of Calgary), Sophie Plamondon(Université de Sherbrooke), Brendan P. Halloran(University of Alberta), Chadwick Williams, Usha Chauhan(Hamilton Health Sciences), David A. Schwartz(St. Jude Children's Research Hospital), Jonathan B. Meddings(University of Calgary), Greg Rosenfeld(British Columbia Centre on Substance Use)
Cited by 41
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k